Aquatic Capital Management LLC Prothena Corp Public LTD CO Transaction History

Aquatic Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $141,075 - $231,761	-5,700 Reduced 82.61%	1,200 $29,000
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $297,252 - $481,344	-9,200 Reduced 57.14%	6,900 $251,000
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $761,530 - $1.14 Million	16,100 New	16,100 $777,000
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $136,213 - $168,983	-2,900 Reduced 29.29%	7,000 $339,000
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $515,295 - $643,500	9,900 New	9,900 $596,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $45,460 - $79,960	-2,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $42,378 - $68,908	1,400 Added 233.33%	2,000 $73,000
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $25,266 - $43,956	600 New	600 $30,000

182

42.7M

77.7K

92.7K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $785M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.